Darzalex (Daratumumab): First Anti-CD38 Monoclonal Antibody Approved for Patients with Relapsed Multiple Myeloma
Daratumumab Biosimilar, Research Grade | CD38 mAb - Ushelf
Frontiers | Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma
Diagnostics | Free Full-Text | Complete Depletion of Daratumumab Interference in Serum Samples from Plasma Cell Myeloma Patients Improves the Detection of Endogenous M-Proteins in a Preliminary Study
Diagnostics | Free Full-Text | Complete Depletion of Daratumumab Interference in Serum Samples from Plasma Cell Myeloma Patients Improves the Detection of Endogenous M-Proteins in a Preliminary Study
Figure 1 from Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA) | Semantic Scholar
Anti Daratumumab Antibody, clone AbD44786ia | Bio-Rad
SEBIA HYDRASHIFT 2/4 daratumumab test kit | Medical Supply Company
Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference
Daratumumab - wikidoc
Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference
Understanding DARZALEX and DARZALEX FASPRO by International Myeloma Foundation - Issuu
Investigation into the interference of the monoclonal antibody daratumumab on the free light chain assay. | Semantic Scholar
How to get clearer test results on monoclonal antibodies
DARZALEX® (daratumumab) Approved by U.S. FDA in Combination with Two Standard of Care Regimens for the Treatment of Patients with Multiple Myeloma Who Have Received At Least One Prior Therapy
Investigation into the interference of the monoclonal antibody daratumumab on the free light chain assay - ScienceDirect
Limited efficacy of daratumumab in multiple myeloma with extramedullary disease | Leukemia
Implications for the monitoring of patients with multiple myeloma undergoing treatment with the anti-CD38 monoclonal daratumumab - Sally Thirkettle, Joanne Russell, Sarah Wilson, Tasneem Ganijee, Samar Kulkarni, Jim Cavet, Phillip J Monaghan,
Case 966-- Clinical Chemistry Case
Current use of monoclonal antibodies in the treatment of multiple myeloma - Varga - 2018 - British Journal of Haematology - Wiley Online Library
Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials | Scientific Reports
U.S. Food and Drug Administration Approves DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj), a New Subcutaneous Formulation of Daratumumab in the Treatment of Patients with Multiple Myeloma
